|
Baseline hematological malignancies
|
|
Acute lymphoid leukemia
|
125 (74)
|
44 (26)
|
|
Chronic lymphoid leukemia
|
340 (71.7)
|
134 (28.3)
|
|
Acute myeloid leukemia
|
298 (60)
|
199 (40)
|
|
Chronic myeloid leukemia
|
144 (89.5)
|
17 (10.5)
|
|
Myelodysplastic syndrome
|
161 (57.7)
|
118 (42.3)
|
|
Low-intermediate risk
|
77 (55.8)
|
61 (44.2)
|
|
High risk
|
26 (54.2)
|
22 (45.8)
|
|
Not stated
|
58 (62.4)
|
35 (37.6)
|
|
Hairy cell leukemia
|
15 (65.2)
|
8 (34.8)
|
|
Hodgkin lymphoma
|
120 (88.9)
|
15 (11.1)
|
|
Non-Hodgkin lymphoma
|
739 (68.2)
|
345 (31.8)
|
|
Indolent
|
354 (71.3)
|
143 (28.7)
|
|
Aggressive
|
337 (65.3)
|
179 (34.7)
|
|
Not stated
|
48 (67.6)
|
23 (32.4)
|
|
Essential thrombocythemia
|
57 (82.6)
|
12 (17.4)
|
|
Myelofibrosis
|
77 (63.1)
|
45 (36.9)
|
|
Polycythemia vera
|
56 (80)
|
14 (20)
|
|
Systemic mastocytosis
|
5 (83.4)
|
1 (16.6)
|
|
Multiple Myeloma
|
458 (67)
|
226 (33)
|
|
Amyloidosis
|
7 (87.5)
|
1 (12.5)
|
|
Aplastic anemia
|
14 (70)
|
6 (30)
|
|
Last/ongoing treatment strategy before COVID-19
|
|
Anagrelide/Hydroxyurea
|
106 (73.1)
|
39 (26.9)
|
|
Conventional chemotherapy
|
423 (70.9)
|
174 (29.1)
|
|
Hypomethylating agents
|
58 (41.2)
|
83 (58.8)
|
|
Immunotherapy only
|
89 (71.2)
|
36 (28.8)
|
|
Immunochemotherapy
|
595 (69.4)
|
262 (30.6)
|
|
Immunomodulators
|
139 (63.8)
|
79 (36.2)
|
|
Targeted therapya
|
453 (74.6)
|
154 (25.4)
|
|
Allogeneic HSCT
|
130 (75.2)
|
43 (24.8)
|
|
Autologous HSCT
|
54 (73)
|
20 (27)
|
|
CAR-T
|
11 (52.4)
|
10 (47.6)
|
|
Radiotherapy
|
9 (90)
|
1 (10)
|
|
Palliative/supportive measures
|
122
(56)
|
104 (46)
|
|
Other
|
17 (60.7)
|
11 (39.3)
|
|
Unknown
|
28 (68.3)
|
13 (31.7)
|
|
No treatment
|
382 (71)
|
156 (29)
|
